382 related articles for article (PubMed ID: 17371768)
1. [Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance].
Dieras V; Vincent-Salomon A; Degeorges A; Beuzeboc P; Mignot L; de Cremoux P
Bull Cancer; 2007 Mar; 94(3):259-66. PubMed ID: 17371768
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
Nahta R; Yu D; Hung MC; Hortobagyi GN; Esteva FJ
Nat Clin Pract Oncol; 2006 May; 3(5):269-80. PubMed ID: 16683005
[TBL] [Abstract][Full Text] [Related]
3. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
4. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
5. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
Chan CT; Metz MZ; Kane SE
Breast Cancer Res Treat; 2005 May; 91(2):187-201. PubMed ID: 15868447
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab-resistant HER2-driven breast cancer cells are sensitive to epigallocatechin-3 gallate.
Eddy SF; Kane SE; Sonenshein GE
Cancer Res; 2007 Oct; 67(19):9018-23. PubMed ID: 17909003
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab: mechanisms of resistance and therapeutic opportunities.
Calabrich A; Fernandes Gdos S; Katz A
Oncology (Williston Park); 2008 Oct; 22(11):1250-8; discussion 1259, 1263. PubMed ID: 18980023
[TBL] [Abstract][Full Text] [Related]
9. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.
Nagata Y; Lan KH; Zhou X; Tan M; Esteva FJ; Sahin AA; Klos KS; Li P; Monia BP; Nguyen NT; Hortobagyi GN; Hung MC; Yu D
Cancer Cell; 2004 Aug; 6(2):117-27. PubMed ID: 15324695
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of Rac1 reduces Trastuzumab resistance in PTEN deficient and insulin-like growth factor I receptor overexpressing human breast cancer SKBR3 cells.
Zhao Y; Wang Z; Jiang Y; Yang C
Cancer Lett; 2011 Dec; 313(1):54-63. PubMed ID: 21943825
[TBL] [Abstract][Full Text] [Related]
12. Her2-positive breast cancer: herceptin and beyond.
Dean-Colomb W; Esteva FJ
Eur J Cancer; 2008 Dec; 44(18):2806-12. PubMed ID: 19022660
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
14. Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.
Gallardo A; Lerma E; Escuin D; Tibau A; Muñoz J; Ojeda B; Barnadas A; Adrover E; Sánchez-Tejada L; Giner D; Ortiz-Martínez F; Peiró G
Br J Cancer; 2012 Apr; 106(8):1367-73. PubMed ID: 22454081
[TBL] [Abstract][Full Text] [Related]
15. [Her2 a paradigm for targeted therapy].
Marijon H; André F
Bull Cancer; 2011 Oct; 98(9):1011-7. PubMed ID: 21684838
[TBL] [Abstract][Full Text] [Related]
16. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells.
Asanuma H; Torigoe T; Kamiguchi K; Hirohashi Y; Ohmura T; Hirata K; Sato M; Sato N
Cancer Res; 2005 Dec; 65(23):11018-25. PubMed ID: 16322251
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.
Fabi A; Metro G; Di Benedetto A; Nisticò C; Vici P; Melucci E; Antoniani B; Perracchio L; Sperduti I; Milella M; Cognetti F; Mottolese M
Oncology; 2010; 78(2):141-9. PubMed ID: 20389136
[TBL] [Abstract][Full Text] [Related]
18. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
Dua R; Zhang J; Nhonthachit P; Penuel E; Petropoulos C; Parry G
Breast Cancer Res Treat; 2010 Aug; 122(3):685-97. PubMed ID: 19859802
[TBL] [Abstract][Full Text] [Related]
19. Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer.
Chandarlapaty S; Sakr RA; Giri D; Patil S; Heguy A; Morrow M; Modi S; Norton L; Rosen N; Hudis C; King TA
Clin Cancer Res; 2012 Dec; 18(24):6784-91. PubMed ID: 23092874
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer.
Mukohara T
Cancer Sci; 2011 Jan; 102(1):1-8. PubMed ID: 20825420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]